NURPF Stock Price, Chart, Stats & News

Neuren Pharmaceuticals Limited
Save
Neuren Pharmaceuticals Limited (NURPF) does not currently pay a dividend.
2.16B
Market cap
109.43x
Current P/E
78.13x
Forward P/E
NURPF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Neuren Pharmaceuticals Limited is a biopharmaceutical company specializing in the development of treatments for neurological conditions. Their leading therapeutic compound, trofinetide, is currently undergoing pivotal (Phase III) clinical trials for Rett syndrome, and has also successfully completed Phase II trials targeting Fragile X syndrome. The company is also progressing NNZ-2591, which has finished its initial human trials (Phase I) for a spectrum of rare neurodevelopmental disorders, including Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes.
Similar securities
Based on sector and market capitalization
Report issue





